Coherus BioSciences, Inc. (NASDAQ:CHRS) Holdings Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 13.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 964,327 shares of the biotechnology company’s stock after buying an additional 116,217 shares during the period. Charles Schwab Investment Management Inc. owned about 0.84% of Coherus BioSciences worth $1,003,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CHRS. Los Angeles Capital Management LLC boosted its position in Coherus BioSciences by 344.1% during the third quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock valued at $967,000 after purchasing an additional 720,672 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Coherus BioSciences in the 2nd quarter valued at approximately $1,246,000. Marshall Wace LLP grew its stake in shares of Coherus BioSciences by 177.3% in the 2nd quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company’s stock valued at $727,000 after buying an additional 268,763 shares in the last quarter. XTX Topco Ltd increased its holdings in Coherus BioSciences by 304.9% in the second quarter. XTX Topco Ltd now owns 271,433 shares of the biotechnology company’s stock worth $470,000 after buying an additional 204,391 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its stake in Coherus BioSciences by 10.6% in the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 9,905 shares during the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus BioSciences Trading Up 0.6 %

NASDAQ:CHRS opened at $1.71 on Wednesday. The firm has a market capitalization of $197.01 million, a PE ratio of -21.38 and a beta of 0.86. Coherus BioSciences, Inc. has a 1 year low of $0.66 and a 1 year high of $3.70. The firm’s fifty day simple moving average is $1.06 and its 200 day simple moving average is $1.30.

Analysts Set New Price Targets

Several analysts have commented on CHRS shares. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Robert W. Baird raised their target price on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Coherus BioSciences in a research report on Wednesday, December 4th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.